Mixed Chimeric Transplantation for Primary Amyloidosis

Status

Withdrawn

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00186095

Enrollment

Registered

2005-09-16

Start date

2000-12-31

Completion date

2006-09-30

Last updated

2022-06-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amyloidosis

Keywords

Amyloidosis, nonmyeloablative, hematopoietic, cell transplantation

Brief summary

To evaluate the role of nonmyeloablative allogeneic transplantation in Amyloidosis.

Interventions

PROCEDUREautologous followed by nonmyeloablative allogeneic transplant

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

No minimum to 60 Years

Healthy volunteers

Inclusion criteria

* primary amyloidosis * adequate organ function * matched sibling donor

Exclusion criteria

* evidence of multiple myeloma * HIV positive

Design outcomes

Primary

Measure	Time frame
Treatment of patients with nonmyeloablative allogeneic transplant for amyloidosis.	—

Secondary

Measure	Time frame
Toxicity of therapy	—
Changes in marrow and serum abnormalities	—
Improvement in end-organ function.	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026